Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

October 5, 2022

Study Completion Date

November 14, 2022

Conditions
Methamphetamine Intoxication (Disorder)
Interventions
BIOLOGICAL

IXT-m200

IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.

DRUG

Lorazepam

Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.

DRUG

Haloperidol

Haloperidol is commonly used to treat agitation due to psychosis.

Trial Locations (4)

72205

University of Arkansas for Medical Sciences, Little Rock

87106

University of New Mexico Hospital, Albuquerque

98201

Providence Regional Medical Center Everett, Everett

99204

Sacred Heart Medical Center, Spokane

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

InterveXion Therapeutics, LLC

INDUSTRY